Cuba's biotechnological industry has made major achievements, including 38 products that are being commercialized in 40 countries.
The most relevant products are the vaccine against meningococcal meningitis, interferon and streptokinase.

As a result of the development of Cuba's biotechnological industry, 140 products have been patented in more than 40 countries, and they may increase to 216 in 2008.

In addition, Cuba's public health system has been supplied with important products such as the vaccine against hepatitis B and recombinant streptokinase to treat patients suffering from acute myocardial infarctions.

Other products are the Heberpenta vaccine, which immunizes children against diphtheria, whooping cough, tetanus, hepatitis B and Haemophilus influenzae, and Heberprot-P, the only medication in the world to treat ulcers caused by diabetic foot.

Scientists are also working on vaccines against hepatitis B and C, prostate cancer, AIDS and dengue fever.
(DTCNews)